When will selumetinib be included in medical insurance?

The novelMEK 1/2 inhibitor selumetinib is only approved for the treatment of neurofibromatosis type 1 (NF-1) in a limited age group. Neurofibromatosis type 1 is considered rare, with an estimated incidence of 1/3000 people. It is an inherited autosomal dominant disorder caused by mutations in the NF1 gene and can lead to various complications, including the development of multiple tumors in the nervous system.

Some patients with this disease develop plexiform neurofibromas(PN); however, this is considered to be relatively uncommon compared to other variants of neurofibromatosis type 1. Fortunately, the use of selumetinib in patients with neurofibromatosis type 1 has shown efficacy in shrinking associated tumors and has been associated with other positive clinical outcomes. Selumetinib has extremely low off-target activity, which contributes to its impressive safety profile, and it demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation in Phase II trials for the treatment of various tumor types.

SelumetinibThe original drug has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The specific time is not yet known. The price of common specifications10mg*60 capsules per box may be more than 20,000 yuan, which is relatively expensive. Selumetiniboriginal drug marketed overseas, specifications10mg*60 capsules per box may cost more than RMB 50,000 (the price may fluctuate due to exchange rates). The ingredients of the original selumetinib sold domestically and abroad are basically the same. There is currently no generic version of selumetinib produced and marketed. For more drug information and specific prices, please consult the medical consultant of Yaode.